Conjugate linker 1

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 208230

CAS#: 1637561-55-7

Description: Conjugate linker 1 crossing linking peptides/proteins with other molecules

Chemical Structure

img
Conjugate linker 1
CAS# 1637561-55-7
Instruction

Theoretical Analysis

MedKoo Cat#: 208230
Name: Conjugate linker 1
CAS#: 1637561-55-7
Chemical Formula: C12H11NO7
Exact Mass: 281.05
Molecular Weight: 281.220
Elemental Analysis: C, 51.25; H, 3.94; N, 4.98; O, 39.82

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Conjugate linker1, Conjugate-linker 1, Conjugate-linker-1

IUPAC/Chemical Name: (2,5-Dioxopyrrolidin-1-yl) 3-(4-methyl-2,5-dioxofuran-3-yl)propanoate

InChi Key: LSZZJVWSEOVRNO-UHFFFAOYSA-N

InChi Code: InChI=1S/C12H11NO7/c1-6-7(12(18)19-11(6)17)2-5-10(16)20-13-8(14)3-4-9(13)15/h2-5H2,1H3

SMILES Code: O=C(ON1C(CCC1=O)=O)CCC2=C(C)C(OC2=O)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 281.22 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x



1: Tsuchikama K, An Z. Antibody-drug conjugates: recent advances in conjugation and linker chemistries. Protein Cell. 2018 Jan;9(1):33-46. doi: 10.1007/s13238-016-0323-0. Epub 2016 Oct 14. PMID: 27743348; PMCID: PMC5777969.


2: Alas M, Saghaeidehkordi A, Kaur K. Peptide-Drug Conjugates with Different Linkers for Cancer Therapy. J Med Chem. 2021 Jan 14;64(1):216-232. doi: 10.1021/acs.jmedchem.0c01530. Epub 2020 Dec 31. PMID: 33382619; PMCID: PMC8610607.


3: Kufka R, Rennert R, Kaluđerović GN, Weber L, Richter W, Wessjohann LA. Synthesis of a tubugi-1-toxin conjugate by a modulizable disulfide linker system with a neuropeptide Y analogue showing selectivity for hY1R-overexpressing tumor cells. Beilstein J Org Chem. 2019 Jan 10;15:96-105. doi: 10.3762/bjoc.15.11. PMID: 30680044; PMCID: PMC6334802.


4: Goldenberg DM, Sharkey RM. Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecan. MAbs. 2019 Aug/Sep;11(6):987-995. doi: 10.1080/19420862.2019.1632115. Epub 2019 Jul 18. PMID: 31208270; PMCID: PMC6748572.


5: Panowski S, Bhakta S, Raab H, Polakis P, Junutula JR. Site-specific antibody drug conjugates for cancer therapy. MAbs. 2014 Jan-Feb;6(1):34-45. doi: 10.4161/mabs.27022. PMID: 24423619; PMCID: PMC3929453.


6: Gymnopoulos M, Betancourt O, Blot V, Fujita R, Galvan D, Lieuw V, Nguyen S, Snedden J, Stewart C, Villicana J, Wojciak J, Wong E, Pardo R, Patel N, D'Hooge F, Vijayakrishnan B, Barry C, Hartley JA, Howard PW, Newman R, Coronella J. TR1801-ADC: a highly potent cMet antibody-drug conjugate with high activity in patient-derived xenograft models of solid tumors. Mol Oncol. 2020 Jan;14(1):54-68. doi: 10.1002/1878-0261.12600. Epub 2019 Dec 3. PMID: 31736230; PMCID: PMC6944112.


7: Wei D, Yu W, Hu C, Shen L, Hu T. The phenyl linker markedly increases the immunogenicity of the pneumococcal polysaccharide conjugate vaccine. Biotechnol Lett. 2018 Aug;40(8):1263-1270. doi: 10.1007/s10529-018-2575-7. Epub 2018 May 25. PMID: 29802568.


8: Cheng X, Li J, Tanaka K, Majumder U, Milinichik AZ, Verdi AC, Maddage CJ, Rybinski KA, Fernando S, Fernando D, Kuc M, Furuuchi K, Fang F, Uenaka T, Grasso L, Albone EF. MORAb-202, an Antibody-Drug Conjugate Utilizing Humanized Anti- human FRα Farletuzumab and the Microtubule-targeting Agent Eribulin, has Potent Antitumor Activity. Mol Cancer Ther. 2018 Dec;17(12):2665-2675. doi: 10.1158/1535-7163.MCT-17-1215. Epub 2018 Sep 27. PMID: 30262588.


9: Abedi M, Cohan RA, Mahboudi F, Faramarzi MA, Fazel R, Damavandi N, Ardestani MS, Davami F. Novel trastuzumab-DM1 conjugate: Synthesis and bio-evaluation. J Cell Physiol. 2019 Aug;234(10):18206-18213. doi: 10.1002/jcp.28453. Epub 2019 Mar 10. PMID: 30854662.


10: Shan L. 64Cu-1,4,7-Triazacyclononane-1,4-diacetic acid-9-aminonanoic acid-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2. 2011 Jan 2 [updated 2011 Jan 25]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. PMID: 21290625.